Table 1

Clinical characteristics of patients with and without carotid artery calcification
All (n = 195) CAAC (+) (n = 128) CAAC (−) (n = 67) p values
Age 68.8 ± 11.3 71.9 ± 9.4 62.7 ± 12.3 <0.01
Male 129 (66) 91 (71) 38 (57) 0.046
Hypertension 171 (88) 120 (94) 51 (76) <0.01
Diabetes mellitus 92 (47) 72 (56) 20 (30) <0.01
Smoking 110 (56) 82 (64) 28 (42) <0.01
Dyslipidemia 146 (75) 102 (80) 44 (66) 0.03
Body mass index (kg/m2) 22.5 ± 4.5 22.3 ± 4.4 22.8 ± 4.6 0.45
Proteinuria (g/day) 1.2 (0.3-3.3) 1.8 (0.3-3.6) 0.9 (0.3-1.9) 0.06
C-reactive protein (mg/dL) 0.09 (0.04-0.22) 0.09 (0.04-0.24) 0.09 (0.03-0.19) 0.22
Hemoglobin (g/dL) 10.7 ± 2.1 10.3 ± 2.0 11.4 ± 2.2 <0.01
eGFR (ml/min/1.73m2) 23.2 (14.5-43.8) 20.0 (13.7-37.2) 34.3 (17.5-60.2) <0.01
Serum corrected calcium (mg/dL) 9.4 ± 0.5 9.5 ± 0.6 9.3 ± 0.5 0.14
Serum phosphorus (mg/dL) 3.7 ± 0.7 3.8 ± 0.8 3.7 ± 0.7 0.80
Ca-P product (mg2/dL2) 35.3 ± 7.0 35.6 ± 7.2 34.6 ± 6.7 0.73
PTH (pg/mL) 73 (45–117) 82 (46–125) 56 (40–88) 0.03
1,25(OH)2Vitamin D (pg/mL) 25 (17–40) 24 (15–36) 30 (22–46) <0.01
FGF23 (pg/mL) 64 (41–105) 73 (48–123) 50 (36–69) <0.01

Values are expressed as the means ± SD, number (percent), or median (interquartile range).

CAAC carotid artery calcification, eGFR estimated glomerular filtration rate, Ca-P calcium-phosphorus, PTH parathyroid hormone, FGF fibroblast growth factor.

Nakayama et al.

Nakayama et al. BMC Nephrology 2013 14:22   doi:10.1186/1471-2369-14-22

Open Data